Dizal presents updated PhII PTLC data, plans to file for accelerated approval in the US next year

Dizal said its peripheral T-cell lymphoma drug candidate showed positive efficacy and safety in a Phase II registrational trial, paving the way for a US filing in what has been a challenging indication to secure full approval.

The single-arm JACKPOT8 Part B investigated golidocitinib — a JAK1 selective inhibitor —…
Click here to view original post